|Bid||1.3600 x 3200|
|Ask||1.3600 x 1400|
|Day's Range||1.3000 - 1.4050|
|52 Week Range||0.6660 - 3.1400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is doubtless a positive to see that the AgeX Therapeutics, Inc. (NYSEMKT:AGE) share price has gained some 80% in...
AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeX’s research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs.
AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX intends to provide the Exchange staff with a plan by July 1, 2020 advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021.